CLINICAL TRIALS PROFILE FOR BETRIXABAN

All Clinical Trials for betrixaban

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00375609 ↗	Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT)	Completed	Portola Pharmaceuticals	Phase 2	2006-05-01	Randomized study of PRT054021 40 mg and 15 mg bid vs. enoxaparin 30 mg q12h for the prophylaxis of venous thromboembolic events after unilateral knee replacement surgery.
NCT00742859 ↗	Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin	Completed	Portola Pharmaceuticals	Phase 2	2008-10-01	Prevention of stroke in patients with atrial fibrillation (AF). Hypothesis: In patients with non-valvular AF, orally administered betrixaban will provide similar or better efficacy and safety than warfarin and it will offer the advantage of not requiring dose adjustments due to international normalized ratios (INRs) outside the target range of 2.0 to 3.0 and a more consistent level of anticoagulation over time.
NCT00999336 ↗	A Study to Determine the Pharmacokinetics, Pharmacodynamics, and Tolerabiltiy of Betrixaban in Patients With Mild, Moderate, and Severe Renal Impairment	Completed	Merck Sharp & Dohme Corp.	Phase 1	2009-07-01	The purpose of the study is to compare the pharmacokinetics, pharmacodynamics, and tolerability of betrixaban in patients with mild, moderate, and severe renal impairment to healthy volunteers.
NCT00999336 ↗	A Study to Determine the Pharmacokinetics, Pharmacodynamics, and Tolerabiltiy of Betrixaban in Patients With Mild, Moderate, and Severe Renal Impairment	Completed	Portola Pharmaceuticals	Phase 1	2009-07-01	The purpose of the study is to compare the pharmacokinetics, pharmacodynamics, and tolerability of betrixaban in patients with mild, moderate, and severe renal impairment to healthy volunteers.
NCT01229254 ↗	Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter	Completed	Portola Pharmaceuticals	Phase 2	2010-09-01	The primary purpose of this study is to optimize drug exposure in the target population.
NCT01229254 ↗	Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter	Completed	Merck Sharp & Dohme Corp.	Phase 2	2010-09-01	The primary purpose of this study is to optimize drug exposure in the target population.

Clinical Trial Conditions for betrixaban

Condition Name

Condition Name for betrixaban
Intervention	Trials
Atrial Fibrillation	2
Healthy	1
Healthy Subjects	1
Hepatic Impairment	1

Condition MeSH

Condition MeSH for betrixaban
Intervention	Trials
Atrial Fibrillation	2
Thromboembolism	2
Venous Thromboembolism	1
Atrial Flutter	1

Clinical Trial Locations for betrixaban

Trials by Country

Trials by Country for betrixaban
Location	Trials
United States	47
Canada	7
Spain	6
Australia	4
South Africa	3

Trials by US State

Trials by US State for betrixaban
Location	Trials
California	4
Florida	3
Ohio	2
Georgia	2
Virginia	2

Clinical Trial Progress for betrixaban

Clinical Trial Phase

Clinical Trial Phase for betrixaban
Clinical Trial Phase	Trials
Phase 3	1
Phase 2	4
Phase 1	5

Clinical Trial Status

Clinical Trial Status for betrixaban
Clinical Trial Phase	Trials
Completed	9
Terminated	1

Clinical Trial Sponsors for betrixaban

Sponsor Name

Sponsor Name for betrixaban
Sponsor	Trials
Portola Pharmaceuticals	11
Merck Sharp & Dohme Corp.	2

Sponsor Type

Sponsor Type for betrixaban
Sponsor	Trials
Industry	13